Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Mar 6;82(7):1327–1331. doi: 10.1054/bjoc.1999.1099

Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model

H Takeshita 1,3, K Kusuzaki 1, H Murata 1, T Suginoshita 1, M Hirata 1, S Hashiguchi 1, T Ashihara 2, M C Gebhardt 4, H J Mankin 4, Y Hirasawa 1
PMCID: PMC2374486  PMID: 10755409

Abstract

A recent study of multidrug resistance (MDR) 1 gene transfected osteosarcoma cells found a cause-effect relationship between increased expression of P-glycoprotein (P-gp) and a low aggressive phenotype. However, several experimental and clinical studies have observed contradictory findings in that P-gp expression has been associated with tumour progression. In the present study, we characterized P-gp-positive and P-gp-negative single-cell clones of a murine osteosarcoma, to further investigate the relationship between P-gp expression and changes in cell phenotype. Although these clones were all selected by doxorubicin (DOX) exposure, they were heterogeneous with respect to MDR1 gene expression. The P-gp-positive clones revealed MDR phenotype, whereas the P-gp-negative clones showed no resistance to drugs. Morphological and functional analysis showed that both the P-gp-positive and P-gp-negative clones were more differentiated than the parent cells in terms of enhanced activity of cellular alkaline phosphatase, an increase in well-organized actin stress fibres and enhanced osteogenic activity. Moreover, these subclones all displayed a decrease in malignant potential such as oncogenic activity, tumour growth rate and metastatic ability, regardless of their P-gp status. These results indicate that the observed osteoblastic differentiation and less aggressive phenotype in DOX-selected osteosarcoma cells may not only be explained by the direct effect of P-gp, and accordingly, consideration of the effect of DOX, as well as P-gp, appears to be important. © 2000 Cancer Research Campaign

Keywords: P-glycoprotein, multidrug resistance, differentiation, malignancy, osteosarcoma

Full Text

The Full Text of this article is available as a PDF (308.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldini N., Scotlandi K., Barbanti-Bròdano G., Manara M. C., Maurici D., Bacci G., Bertoni F., Picci P., Sottili S., Campanacci M. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995 Nov 23;333(21):1380–1385. doi: 10.1056/NEJM199511233332103. [DOI] [PubMed] [Google Scholar]
  2. Biedler J. L. Drug resistance: genotype versus phenotype--thirty-second G. H. A. Clowes Memorial Award Lecture. Cancer Res. 1994 Feb 1;54(3):666–678. [PubMed] [Google Scholar]
  3. Biedler J. L., Spengler B. A. Reverse transformation of multidrug-resistant cells. Cancer Metastasis Rev. 1994 Jun;13(2):191–207. doi: 10.1007/BF00689636. [DOI] [PubMed] [Google Scholar]
  4. Bosch I., Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta. 1996 Oct 9;1288(2):F37–F54. doi: 10.1016/0304-419x(96)00022-4. [DOI] [PubMed] [Google Scholar]
  5. Bradley G., Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 1994 Jun;13(2):223–233. doi: 10.1007/BF00689638. [DOI] [PubMed] [Google Scholar]
  6. Bradley G., Sharma R., Rajalakshmi S., Ling V. P-glycoprotein expression during tumor progression in the rat liver. Cancer Res. 1992 Oct 1;52(19):5154–5161. [PubMed] [Google Scholar]
  7. Chan H. S., Haddad G., Thorner P. S., DeBoer G., Lin Y. P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 Dec 5;325(23):1608–1614. doi: 10.1056/NEJM199112053252304. [DOI] [PubMed] [Google Scholar]
  8. Fairchild C. R., Ivy S. P., Rushmore T., Lee G., Koo P., Goldsmith M. E., Myers C. E., Farber E., Cowan K. H. Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7701–7705. doi: 10.1073/pnas.84.21.7701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fardel O., Lecureur V., Daval S., Corlu A., Guillouzo A. Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem. 1997 May 15;246(1):186–192. doi: 10.1111/j.1432-1033.1997.t01-1-00186.x. [DOI] [PubMed] [Google Scholar]
  10. Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989 May 12;119(2):203–210. doi: 10.1016/0022-1759(89)90397-9. [DOI] [PubMed] [Google Scholar]
  11. Hirsch-Ernst K. I., Ziemann C., Foth H., Kozian D., Schmitz-Salue C., Kahl G. F. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J Cell Physiol. 1998 Sep;176(3):506–515. doi: 10.1002/(SICI)1097-4652(199809)176:3<506::AID-JCP7>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  12. Hirsch-Ernst K. I., Ziemann C., Schmitz-Salue C., Foth H., Kahl G. F. Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun. 1995 Oct 4;215(1):179–185. doi: 10.1006/bbrc.1995.2450. [DOI] [PubMed] [Google Scholar]
  13. Mickley L. A., Bates S. E., Richert N. D., Currier S., Tanaka S., Foss F., Rosen N., Fojo A. T. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem. 1989 Oct 25;264(30):18031–18040. [PubMed] [Google Scholar]
  14. Morceau F., Chénais B., Gillet R., Jardillier J. C., Jeannesson P., Trentesaux C. Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Cell Growth Differ. 1996 Aug;7(8):1023–1029. [PubMed] [Google Scholar]
  15. Scotlandi K., Manara M. C., Serra M., Benini S., Maurici D., Caputo A., De Giovanni C., Lollini P. L., Nanni P., Picci P. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene. 1999 Jan 21;18(3):739–746. doi: 10.1038/sj.onc.1202330. [DOI] [PubMed] [Google Scholar]
  16. Scotlandi K., Serra M., Nicoletti G., Vaccari M., Manara M. C., Nini G., Landuzzi L., Colacci A., Bacci G., Bertoni F. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 1996 May 15;56(10):2434–2439. [PubMed] [Google Scholar]
  17. Serra M., Scotlandi K., Manara M. C., Maurici D., Benini S., Sarti M., Campanacci M., Baldini N. Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer. 1995 Nov;31A(12):1998–2002. doi: 10.1016/0959-8049(95)00335-5. [DOI] [PubMed] [Google Scholar]
  18. Takeshita H., Gebhardt M. C., Springfield D. S., Kusuzaki K., Mankin H. J. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg Am. 1996 Mar;78(3):366–375. doi: 10.2106/00004623-199603000-00007. [DOI] [PubMed] [Google Scholar]
  19. Takeshita H., Kusuzaki K., Tsuji Y., Hirata M., Hashiguchi S., Nakamura S., Murata H., Ashihara T., Hirasawa Y. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209. Anticancer Res. 1998 Mar-Apr;18(2A):739–742. [PubMed] [Google Scholar]
  20. Uchiumi T., Kohno K., Tanimura H., Matsuo K., Sato S., Uchida Y., Kuwano M. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ. 1993 Mar;4(3):147–157. [PubMed] [Google Scholar]
  21. Weinstein R. S., Jakate S. M., Dominguez J. M., Lebovitz M. D., Koukoulis G. K., Kuszak J. R., Klusens L. F., Grogan T. M., Saclarides T. J., Roninson I. B. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991 May 15;51(10):2720–2726. [PubMed] [Google Scholar]
  22. Wulf E., Deboben A., Bautz F. A., Faulstich H., Wieland T. Fluorescent phallotoxin, a tool for the visualization of cellular actin. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4498–4502. doi: 10.1073/pnas.76.9.4498. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES